Sartorius reported that it will open expanded production facilities in Ajdovscina, Slovenia. The area for manufacturing and labs will increase from 3,000 m2 to 6,200 m2.
“The expansion is an important step forward and will enable our business to develop and grow to meet the requirements of our customers in a rapidly expanding industry. It will particularly enhance our unique offering for the manufacturing of gene therapies and other advanced therapies,” said Joachim Kreuzburg, CEO of Sartorius.
In 2021, Sartorius will invest more than 400 million euros in the expansion of manufacturing capacities around the world to meet the high demand from the growing biopharmaceuticals market, according to company officials.
“With more than 140 employees at its plant in Ajdovscina, Sartorius develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are used in vaccines as well as in cell and gene therapies and other advanced therapies,” added Kreuzburg.
Last November, Sartorius acquired the Slovenian purification specialist BIA Separations in Ajdovscina. Its technology for manufacturing-scale purification is already used in the production of the first commercialized advanced therapeutics, and the company also has a strong presence with drug candidates in the clinical pipeline, noted Kreuzburg.
